{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.3","upperLimit":"39.0","value":"25.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"PR or CR is classified by the investigators according to RECIST criteria version 1.0. PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions; CR is the disappearance of all target and non-target lesions. Percentage of participants having a PR or CR is calculated as a total number of participants with PR or CR from enrollment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cetuximab loading dose of 400 mg/m² administered intravenously on Day 1 of Cycle 1; subsequently 250 mg/m² administered intravenously weekly.\n\nPemetrexed 500 mg/m² administered intravenously on Day 1 of every 21-day cycle, 1 hour after cetuximab.\n\nCarboplatin AUC 5 or cisplatin 75 mg/m² administered intravenously on Day 1 of every 21-day cycle, 30 minutes after pemetrexed.\n\nMaximum 6 cycles. Participants who did not experience disease progression after 6 cycles continued on cetuximab (250 mg/m² intravenously weekly) monotherapy until disease progression.","id":"OG000","title":"Cetuximab + Pemetrexed + Carboplatin/Cisplatin"}],"paramType":"NUMBER","populationDescription":"All treated participants excluding those from a noncompliant study site.","reportingStatus":"POSTED","timeFrame":"From enrollment to objectively determined progressive disease up to 15.3 months (tumor assessments performed every other cycle during study treatment until progressive disease)","title":"Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}